Liraglutide reduces uterine scarring by directly targeting NF-κB to block inflammation and fibrosis | Research

The takeaway

Liraglutide reduced intrauterine adhesions in rat models and human organoids by directly binding NF-κB and inhibiting its phosphorylation, thereby reducing inflammation, collagen fibrosis, and epithelial-mesenchymal transition.

Direct NF-κB target
Liraglutide directly binds NF-κB protein to block fibrosis—a novel mechanism distinct from GLP-1 receptor signaling

What the researchers found

Liraglutide reduced endometrial inflammation, collagen fibrosis, and EMT in IUA rat and human organoid models. NF-κB identified as a direct binding target of liraglutide. Blocking liraglutide-NF-κB interaction attenuated all protective effects.

Why it matters

IUA causes infertility and has limited treatment options. Discovering that a widely available GLP-1 drug can treat uterine scarring through a novel mechanism (direct NF-κB binding) could provide a new off-label therapeutic option.

How the study worked

Rat IUA model (mechanical damage), human endometrial organoids (RU486-induced), primary human cells (TGF-β-treated), H&E/Masson staining, immunohistochemistry, Western blot, SuperPred target prediction, and cellular thermal shift assay.

What this study cannot tell us

Preclinical study. No human clinical trial data. The direct NF-κB binding mechanism is novel and needs independent validation. Doses used may not reflect clinical GLP-1 dosing.

How to read the evidence

Preclinical study with rat, organoid, and primary human cell validation. Novel mechanism well-supported but needs clinical confirmation.

When this study was published

Published in 2025.

The bigger picture

This adds reproductive health to the expanding list of GLP-1 drug applications. The direct NF-κB binding mechanism is novel and distinct from the canonical GLP-1 receptor pathway, suggesting liraglutide has anti-fibrotic properties independent of its metabolic effects.

Questions still open

Could liraglutide be used clinically for IUA prevention after uterine procedures?
Does this NF-κB mechanism contribute to anti-fibrotic effects in other organs?
Would other GLP-1 agonists show the same direct NF-κB targeting?

Common questions

What are intrauterine adhesions?

Intrauterine adhesions (IUA or Asherman's syndrome) are bands of scar tissue that form inside the uterus, usually after surgical procedures. They can cause infertility, menstrual problems, and pregnancy complications. Current treatments have limited success.

How could a diabetes drug help with uterine scarring?

This study found liraglutide has a previously unknown ability to directly bind NF-κB, a key inflammation protein, and prevent it from driving scar formation. This anti-fibrotic mechanism is separate from its metabolic effects and could be applied to prevent or treat uterine scarring.

Read the original research

Liraglutide ameliorates intrauterine adhesion by inhibiting NF-κb phosphorylation and reducing epithelial-mesenchymal transition.

Experimental cell research, 451(2), 114708

View on PubMed ↗Publisher’s paper ↗

Citation

Shi, Jie; Xu, Weicong; Yang, Tao; Bayijuma, Ayana; Huang, Yujie; Zhou, Yunxiao. (2025). Liraglutide ameliorates intrauterine adhesion by inhibiting NF-κb phosphorylation and reducing epithelial-mesenchymal transition.. Experimental cell research, 451(2), 114708. https://doi.org/10.1016/j.yexcr.2025.114708